Acknowledgement
Supported by : National Research Foundation of Korea (NRF)
References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. https://doi.org/10.3322/caac.21442
- Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974-82. https://doi.org/10.1200/JCO.2014.59.4358
- Phan GQ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci. 2003;100(14):8372-7. https://doi.org/10.1073/pnas.1533209100
- Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. https://doi.org/10.1056/NEJMoa1003466
- Kroemer G, Zitvogel L. Cancer immunotherapy in 2017: the breakthrough of the microbiota. Nat Rev Immunol. 2018;18(2):87-8. https://doi.org/10.1038/nri.2018.4
- Byun DJ, et al. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195. https://doi.org/10.1038/nrendo.2016.205
- Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-61. https://doi.org/10.1016/j.ccell.2015.03.001
- Rosenberg SA, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299-308. https://doi.org/10.1038/nrc2355
- Melero I, et al. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4(5):522-6. https://doi.org/10.1158/2159-8290.CD-13-0985
- Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263-74. https://doi.org/10.1038/nrc1586
- Chen F, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13(1):45. https://doi.org/10.1186/s12916-015-0278-7
- Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2016;39:1-6. https://doi.org/10.1016/j.coi.2015.10.009
- Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356-64. https://doi.org/10.1172/JCI80005
- Jo SD, et al. Harnessing designed nanoparticles: current strategies and future perspectives in cancer immunotherapy. Nano Today. 2017;17:23-37. https://doi.org/10.1016/j.nantod.2017.10.008
- Yoon HY, et al. Engineering nanoparticle strategies for effective cancer immunotherapy. Biomaterials. 2018;178:597-607. https://doi.org/10.1016/j.biomaterials.2018.03.036
- Shao K, et al. Nanoparticle-based immunotherapy for cancer. ACS Nano. 2014;9(1):16-30. https://doi.org/10.1021/nn5062029
- Velpurisiva P, et al. Nanoparticle design strategies for effective cancer immunotherapy. J Biomed. 2017;2(2):64-77. https://doi.org/10.7150/jbm.18877
- Santoni M, Cascinu S, Mills CD. Altering macrophage polarization in the tumor environment: the role of response gene to complement 32. Cell Mol Immunol. 2015;12(6):783-4. https://doi.org/10.1038/cmi.2014.115
- Rajendrakumar SK, et al. Nanoparticle-based phototriggered cancer immunotherapy and its domino effect in the tumor microenvironment. Biomacromolecules. 2018;19(6):1869-87. https://doi.org/10.1021/acs.biomac.8b00460
- Weigert A, Brune B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide. 2008;19(2):95-102. https://doi.org/10.1016/j.niox.2008.04.021
- Nesbit M, et al. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol. 2001;166(11):6483-90. https://doi.org/10.4049/jimmunol.166.11.6483
- Ruff M, et al. Neuropeptides are chemoattractants for human tumor cells and monocytes: a possible mechanism for metastasis. Clin Immunol Immunopathol. 1985;37(3):387-96. https://doi.org/10.1016/0090-1229(85)90108-4
- Mantovani A, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25(3):315-22. https://doi.org/10.1007/s10555-006-9001-7
- Bear AS, et al. Elimination of metastatic melanoma using gold nanoshellenabled photothermal therapy and adoptive T cell transfer. PLoS One. 2013;8(7):e69073. https://doi.org/10.1371/journal.pone.0069073
- Wilkerson A, et al. Nanoparticle systems modulating myeloid-derived suppressor cells for cancer immunotherapy. Curr Top Med Chem. 2017;17(16):1843-57. https://doi.org/10.2174/1568026617666161122121412
- Kennedy LC, et al. T cells enhance gold nanoparticle delivery to tumors in vivo. Nanoscale Res Lett. 2011;6(1):283. https://doi.org/10.1186/1556-276X-6-283
- Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25-39. https://doi.org/10.1189/jlb.1212621
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64. https://doi.org/10.1038/nrc3239
- Mocellin S, Nitti D. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta. 2013;1836(2):187-96.
- Ostrand-Rosenberg S. Tolerance and immune suppression in the tumor microenvironment. Cell Immunol. 2016;299:23-9. https://doi.org/10.1016/j.cellimm.2015.09.011
- L-x Z, et al. Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy. Biomaterials. 2018;174:54-66. https://doi.org/10.1016/j.biomaterials.2018.05.015
- Tran TH, et al. Nanoparticles for dendritic cell-based immunotherapy. Int J Pharm. 2018;542(1-2):253-65. https://doi.org/10.1016/j.ijpharm.2018.03.029
- Thomas SN, et al. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials. 2014;35(2):814-24. https://doi.org/10.1016/j.biomaterials.2013.10.003
- Irvine DJ, et al. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev. 2015;115(19):11109-46. https://doi.org/10.1021/acs.chemrev.5b00109
- Reddy ST, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25(10):1159-64. https://doi.org/10.1038/nbt1332
- Zhu G, et al. Efficient nanovaccine delivery in cancer immunotherapy. ACS Nano. 2017;11(3):2387-92. https://doi.org/10.1021/acsnano.7b00978
- Reddy ST, et al. In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles. J Control Release. 2006;112(1):26-34. https://doi.org/10.1016/j.jconrel.2006.01.006
- Toy R, et al. The effects of particle size, density and shape on margination of nanoparticles in microcirculation. Nanotechnology. 2011;22(11):115101. https://doi.org/10.1088/0957-4484/22/11/115101
- Carboni E, et al. Particle margination and its implications on intravenous anticancer drug delivery. AAPS PharmSciTech. 2014;15(3):762-71. https://doi.org/10.1208/s12249-014-0099-6
- Gentile F, et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J Biomech. 2008;41(10):2312-8. https://doi.org/10.1016/j.jbiomech.2008.03.021
- Gratton SE, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci. 2008;105(33):11613-8. https://doi.org/10.1073/pnas.0801763105
- Manolova V, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38(5):1404-13. https://doi.org/10.1002/eji.200737984
- Foged C, et al. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315-22. https://doi.org/10.1016/j.ijpharm.2005.03.035
- Goodman CM, et al. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem. 2004;15(4):897-900. https://doi.org/10.1021/bc049951i
- Dewitte H, et al. Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment. Nano Today. 2014;9(6):743-58. https://doi.org/10.1016/j.nantod.2014.10.001
- Park J, Babensee JE. Differential functional effects of biomaterials on dendritic cell maturation. Acta Biomater. 2012;8(10):3606-17. https://doi.org/10.1016/j.actbio.2012.06.006
- Da Silva CA, et al. Chitin is a size-dependent regulator of macrophage TNF and IL-10 production. J Immunol. 2009;182(6):3573-82. https://doi.org/10.4049/jimmunol.0802113
-
Shima F, et al. Manipulating the antigen-specific immune response by the hydrophobicity of amphiphilic poly(
${\gamma}$ -glutamic acid) nanoparticles. Biomaterials. 2013;34(37):9709-16. https://doi.org/10.1016/j.biomaterials.2013.08.064 - Shekarian T, et al. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann Oncol. 2017;28(8):1756-66. https://doi.org/10.1093/annonc/mdx179
- Hanson MC, et al. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest. 2015;125(6):2532-46. https://doi.org/10.1172/JCI79915
- Chen S, et al. Microfluidic generation of chitosan/CpG oligodeoxynucleotide nanoparticles with enhanced cellular uptake and immunostimulatory properties. Lab Chip. 2014;14(11):1842-9. https://doi.org/10.1039/c4lc00015c
- Luo M, et al. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2017;12(7):648-54. https://doi.org/10.1038/nnano.2017.52
- Wilson JT, et al. pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano. 2013;7(5):3912-25. https://doi.org/10.1021/nn305466z
- Noh YW, et al. Multifaceted immunomodulatory nanoliposomes: reshaping tumors into vaccines for enhanced Cancer immunotherapy. Adv Funct Mater. 2017;27(8):1605398. https://doi.org/10.1002/adfm.201605398
- Jeanbart L, Swartz MA. Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci. 2015;112(47):14467-72. https://doi.org/10.1073/pnas.1508516112
- Ou W, et al. Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy. J Control Release. 2018;281:84-96. https://doi.org/10.1016/j.jconrel.2018.05.018
- Sacchetti C, et al. In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes. Bioconjug Chem. 2013;24(6):852-8. https://doi.org/10.1021/bc400070q
- Lu K, et al. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng. 2018;2:600-10. https://doi.org/10.1038/s41551-018-0203-4
- Lu J, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8(1):1811. https://doi.org/10.1038/s41467-017-01651-9
- Postow MA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-31. https://doi.org/10.1056/NEJMoa1112824
- Demaria S, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862-70. https://doi.org/10.1016/j.ijrobp.2003.09.012
- Dewan MZ, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379-88. https://doi.org/10.1158/1078-0432.CCR-09-0265
- Wilhelm S, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. https://doi.org/10.1038/natrevmats.2016.14
- Phillips WT, et al. Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles. Adv Drug Deliv Rev. 2014;76:39-59. https://doi.org/10.1016/j.addr.2014.07.001
- Park W, et al. Acidic pH-triggered drug-eluting nanocomposites for magnetic resonance imagingmonitored intra-arterial drug delivery to hepatocellular carcinoma. ACS Appl Mater Interfaces. 2016;8(20):12711-9. https://doi.org/10.1021/acsami.6b03505
- Park W, et al. Immunomodulatory magnetic microspheres for augmenting tumor-specific infiltration of natural killer (NK) cells. ACS Appl Mater Interfaces. 2017;9(16):13819-24. https://doi.org/10.1021/acsami.7b02258
- Ahmed M, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. J Vasc Interv Radiol. 2014;25(11):1691-1705.e4. https://doi.org/10.1016/j.jvir.2014.08.027
- Kim D-H. Image-guided Cancer nanomedicine. J Imaging. 2018;4(1):18. https://doi.org/10.3390/jimaging4010018
- Ling D, Lee N, Hyeon T. Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. Acc Chem Res. 2015;48(5):1276-85. https://doi.org/10.1021/acs.accounts.5b00038
- Lu Y, et al. Iron oxide nanoclusters for T 1 magnetic resonance imaging of non-human primates. Nat Biomed Eng. 2017;1(8):637-43. https://doi.org/10.1038/s41551-017-0116-7
- Ling D, et al. Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. J Am Chem Soc. 2014;136(15):5647-55. https://doi.org/10.1021/ja4108287
- Grifantini R, et al. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. J Control Release. 2018;280:76-86. https://doi.org/10.1016/j.jconrel.2018.04.052
- Park W, et al. Branched Gold Nanoparticle Coating of Clostridium novyi-NT Spores for CT-Guided Intratumoral Injection. Small. 2017;13(5):1602722. https://doi.org/10.1002/smll.201602722
- Park JS, et al. Multi-functional nanotracers for image-guided stem cell gene therapy. Nanoscale. 2017;9(14):4665-76. https://doi.org/10.1039/C6NR09090G
- van Hooren L, et al. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2017;47(2):385-93. https://doi.org/10.1002/eji.201646583
- Fransen MF, et al. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T cell dependent tumor eradication and decreases risk of toxic side-effects. Clin Cancer Res. 2013;2012:0781.
- Sandin LC, et al. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology. 2014;3(1):e27614. https://doi.org/10.1186/s40824-018-0133-y.
- Weiden J, Tel J, Figdor CG. Synthetic immune niches for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):212. https://doi.org/10.1038/nri.2017.89
- Sandin LC, et al. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res. 2014;2(1):80-90. https://doi.org/10.1158/2326-6066.CIR-13-0067
- Fransen MF, et al. Local reprogramming of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17(8):2270-80. https://doi.org/10.1158/1078-0432.CCR-10-2888
- Pardi N, et al. mRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-79. https://doi.org/10.1038/nrd.2017.243
- Kreiter S, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692-6. https://doi.org/10.1038/nature14426
- Oberli MA, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2016;17(3):1326-35. https://doi.org/10.1021/acs.nanolett.6b03329
- Sau S, et al. Multifunctional nanoparticles for cancer immunotherapy: a groundbreaking approach for reprogramming malfunctioned tumor environment. J Control Release. 2018;274:24-34. https://doi.org/10.1016/j.jconrel.2018.01.028
- Kuai R, et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci Adv. 2018;4(4):eaao1736. https://doi.org/10.1126/sciadv.aao1736
- Kang TH, et al. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. 2013;73(8):2493-504. https://doi.org/10.1158/0008-5472.CAN-12-4241
- Min Y, et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 2017;12(9):877-82. https://doi.org/10.1038/nnano.2017.113
- He C, et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun. 2016;7:12499. https://doi.org/10.1038/ncomms12499
- Lu K, et al. Chlorin-based nanoscale metal-organic framework systemically rejects colorectal cancers via synergistic photodynamic therapy and checkpoint blockade immunotherapy. J Am Chem Soc. 2016;138(38):12502-10. https://doi.org/10.1021/jacs.6b06663
- Nam J, et al. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018;9(1):1074. https://doi.org/10.1038/s41467-018-03473-9
- Chen Q, et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7:13193. https://doi.org/10.1038/ncomms13193
- Meir R, et al. Fast image-guided stratification using anti-programmed death ligand 1 gold nanoparticles for cancer immunotherapy. ACS Nano. 2017;11(11):11127-34. https://doi.org/10.1021/acsnano.7b05299
- Rhodes KR, Green JJ. Nanoscale artificial antigen presenting cells for cancer immunotherapy. Mol Immunol. 2018;98:13-8. https://doi.org/10.1016/j.molimm.2018.02.016
- Hickey JW, et al. Biologically inspired design of nanoparticle artificial antigen-presenting cells for immunomodulation. Nano Lett. 2017;17(11):7045-54. https://doi.org/10.1021/acs.nanolett.7b03734
Cited by
- New opportunities for nanoparticles in cancer immunotherapy vol.22, pp.1, 2018, https://doi.org/10.1186/s40824-018-0133-y
- Bioactive Nanoparticles for Cancer Immunotherapy vol.19, pp.12, 2018, https://doi.org/10.3390/ijms19123877
- Immunomodulatory Nanosystems vol.6, pp.17, 2018, https://doi.org/10.1002/advs.201900101
- Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials vol.11, pp.10, 2018, https://doi.org/10.3390/pharmaceutics11100534
- Interactions of Nanoparticles and Biosystems: Microenvironment of Nanoparticles and Biomolecules in Nanomedicine vol.9, pp.10, 2019, https://doi.org/10.3390/nano9101365
- Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers vol.26, pp.1, 2018, https://doi.org/10.1186/s12929-019-0583-0
- Immunotherapy: A Challenge of Breast Cancer Treatment vol.11, pp.12, 2018, https://doi.org/10.3390/cancers11121822
- Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting vol.62, pp.23, 2019, https://doi.org/10.1021/acs.jmedchem.9b00511
- Recognition Sites for Cancer-targeting Drug Delivery Systems vol.20, pp.10, 2019, https://doi.org/10.2174/1389200220666191003161114
- Peptide-based targeting of immunosuppressive cells in cancer vol.5, pp.1, 2018, https://doi.org/10.1016/j.bioactmat.2020.01.006
- Nano-immunoimaging vol.5, pp.4, 2018, https://doi.org/10.1039/c9nh00514e
- Materials for Immunotherapy vol.32, pp.13, 2018, https://doi.org/10.1002/adma.201901633
- Application of Nanomaterials in Biomedical Imaging and Cancer Therapy vol.10, pp.9, 2018, https://doi.org/10.3390/nano10091700
- Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy vol.12, pp.11, 2018, https://doi.org/10.3390/cancers12113123
- Emerging nanomedicines for effective breast cancer immunotherapy vol.18, pp.1, 2020, https://doi.org/10.1186/s12951-020-00741-z
- Cationic Nanoparticle-Mediated Activation of Natural Killer Cells for Effective Cancer Immunotherapy vol.12, pp.51, 2018, https://doi.org/10.1021/acsami.0c16357
- Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System vol.16, pp.None, 2021, https://doi.org/10.2147/ijn.s295300
- A Critical Review of the Use of Surfactant-Coated Nanoparticles in Nanomedicine and Food Nanotechnology vol.16, pp.None, 2021, https://doi.org/10.2147/ijn.s298606
- Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics vol.8, pp.None, 2021, https://doi.org/10.3389/fchem.2020.631351
- External and Internal Stimuli-Responsive Metallic Nanotherapeutics for Enhanced Anticancer Therapy vol.7, pp.None, 2018, https://doi.org/10.3389/fmolb.2020.597634
- Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy vol.17, pp.6, 2018, https://doi.org/10.2217/fon-2020-0720
- Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity vol.13, pp.11, 2018, https://doi.org/10.3390/cancers13112735
- Recent Advances in Nanoscale Metal-Organic Frameworks Towards Cancer Cell Cytotoxicity: An Overview vol.31, pp.7, 2021, https://doi.org/10.1007/s10904-021-02011-3
- Nanoparticles in nanomedicine: a comprehensive updated review on current status, challenges and emerging opportunities vol.38, pp.6, 2018, https://doi.org/10.1080/02652048.2021.1942275
- Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy vol.6, pp.9, 2018, https://doi.org/10.1039/d1nh00179e
- Thermoresponsive Chitosan-Grafted-Poly(N-vinylcaprolactam) Microgels via Ionotropic Gelation for Oncological Applications vol.13, pp.10, 2018, https://doi.org/10.3390/pharmaceutics13101654
- Single, binary and successive patterning of charged nanoparticles by electrophoretic deposition vol.23, pp.11, 2018, https://doi.org/10.1007/s11051-021-05368-1
- Nanotechnology-enhanced immunotherapy for metastatic cancer vol.2, pp.4, 2021, https://doi.org/10.1016/j.xinn.2021.100174
- Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective vol.11, pp.11, 2021, https://doi.org/10.3390/nano11112792
- Nanoparticles for Cancer Therapy: Current Progress and Challenges vol.16, pp.1, 2018, https://doi.org/10.1186/s11671-021-03628-6
- Nanoparticles derived from insect exoskeleton modulates NLRP3 inflammasome complex activation in cervical cancer cell line model vol.12, pp.1, 2018, https://doi.org/10.1186/s12645-021-00090-y
- Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development vol.19, pp.1, 2021, https://doi.org/10.1186/s12967-021-03014-x
- Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen vol.22, pp.23, 2021, https://doi.org/10.3390/ijms222313011